The development of pyrrolobenzodiazepines as antitumour agents

By Hartley John A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 733-744

Informa Healthcare

Access to resources Recommend Favorite

The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl) benzothiazole (DF 203) and Related Compounds

By  

Current Medicinal Chemistry, Vol. 8, Iss. 2, 2001-02 ,pp. : 203-210

Bentham Science Publishers

Access to resources Recommend Favorite

Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing Prodrug J1

By Gullbo Joachim   Wickström Malin   Tullberg Marcus   Ehrsson Hans   Lewensohn Rolf   Nygren Peter   Luthman Kristina   Larsson Rolf  

Journal of Drug Targeting, Vol. 11, Iss. 6, 2003-07 ,pp. : 355-363

Informa Healthcare

Access to resources Recommend Favorite

Fosamprenavir: Clinical Pharmacokinetics and Drug Interactions of the Amprenavir Prodrug

By Mary Beth Wire  

Clinical Pharmacokinetics, Vol. 45, Iss. 2, 2006-01 ,pp. : 137-168

Adis International

Access to resources Recommend Favorite

Staged Risk Management of Candidate Drug Efficacy: A Proposed Structure to Classify Levels of Proof Within a Clinical Development Programme

By Smethurst Dominic   Hughes Andrew  

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 4, 2005-01 ,pp. : 227-232

Adis International

Access to resources Recommend Favorite